Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs. Prasugrel Effects on Infarct Size in STEMI (TIPRIS)
NCT02507323Phase 2Withdrawn
- Start
- Feb 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ticagrelor in ST-elevation myocardial infarction (STEMI) (2 arms). Primary endpoint: Infarct Size at Day 90. Planned start Feb 2016; status: withdrawn.
02
Drugs
ticagrelor
03
Conditions
ST-elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT02507323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02507323.